Search the Newsreel

Earnings call transcript: Niagen Bioscience posts q2 2026 growth, lifts spending

Niagen Bioscience (CDXC) reported Q2 2026 revenue of $29.8 million, driven by growth in its Tru Niagen supplement and e-commerce, but net income dropped to $1 million ($0.01 per diluted share) due to increased marketing and product development spending. The company is transitioning into …

The Agency Group Australia Securities Subject to Temporary Trading Pause

QIAGEN NV Revenue Breakdown – BIVA:QIA/N

QIAGEN NV (BIVA:QIA/N) generated 37.68 billion MXN in revenue last year. Its top-performing segment was Diagnostic Solutions, contributing 14.48 billion MXN. The United States was the largest regional contributor, accounting for 18.00 billion MXN of the total revenue.

Is Niagen Bioscience Inc (NAGE) Undervalued After Q2 Earnings Mi

Niagen Bioscience (NASDAQ:NAGE) Announces Quarterly Earnings Results, Meets Expectations

Niagen Bioscience (NASDAQ:NAGE) reported quarterly earnings of $0.01 EPS, which met analyst expectations. The company demonstrated a net margin of 14.29% and a return on equity of 22.68%. Despite the stock trading near its 52-week low, analysts maintain a generally positive "Buy" rating with …

Niagen Bioscience outlines 10% to 15% 2026 e-commerce growth while positioning Niagen Plus and NB4168 for 2027 traction

Earnings Call Insights: Niagen Bioscience (NAGE) Q2 2026 MANAGEMENT VIEW * "This quarter marks another important milestone in the evolution of Niagen Bioscience" (CEO & Director Robert Fried) and "today, we are becoming something much broader, a science-driven platform company built around the biology …

Ultragenyx (RARE) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Ultragenyx (RARE) reported $214 million in revenue for the quarter ended June 2026, representing a year-over-year increase of 28.5%. EPS of -$0.90 for the same period compares to -$1.17 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $181.01 million, …

Ultragenyx (RARE) Reports Q2 Loss, Tops Revenue Estimates

Ultragenyx Pharmaceutical Inc reports results for the quarter ended June 30 - Earnings Summary

Ultragenyx Pharmaceutical Inc has released its earnings summary for the quarter that ended on June 30. The article, sourced from Reuters and republished on TradingView News, provides details on the company's financial performance. To access the full report and more in-depth analysis, readers are …

BRIEF-Exagen Inc. Q2 Revenue USD 19.941 Million Vs. IBES Estimate USD 17.8 Million

Exagen Inc. reported its Q2 revenue at $19.941 million, surpassing the IBES estimate of $17.8 million. The brief financial update indicates a stronger-than-expected performance for the company in the second quarter.

Earnings Flash (RARE) Ultragenyx Pharmaceutical Posts Q2 Loss of $0.90 per Share, vs. FactSet Est $1.22 Loss

Niagen Bioscience, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:NAGE) 2026-08-04

Ultragenyx Reports Second Quarter 2026 Financial Results and Corporate Update

Ultragenyx Pharmaceutical Inc. reported strong financial results for the second quarter of 2026, with total revenue reaching $214 million and reaffirming its full-year revenue guidance of $730 million to $760 million. The company is on track for profitability in 2027 and anticipates significant catalysts …

Earnings Flash (RARE) Ultragenyx Pharmaceutical Inc. Reports Q2 Revenue $214.0M, vs. FactSet Est of $183.1M

Ultragenyx Pharmaceutical Inc. (RARE) reported Q2 revenue of $214.0 million, significantly exceeding the FactSet estimate of $183.1 million. This financial update also noted a Q2 loss of $0.90 per share, which was better than the FactSet estimated loss of $1.22 per share. The biopharmaceutical …

Release according to Article 40, Section 1 of the WpHG

QIAGEN N.V. has released a notification regarding voting rights, as informed by the AFM. T. Rowe Price Group, Inc. reported a transaction on July 29, 2026, showing a capital interest and voting rights distribution of 4.97% in QIAGEN N.V. The company emphasizes it is …

Ultragenyx Pharmaceutical Inc. (RARE) CLO sells 1,900 shares at $24.92

Ultragenyx Pharmaceutical Inc.'s EVP and Chief Legal Officer, Karah Herdman Parschauer, sold 1,900 shares of common stock at $24.92 per share on August 3, 2026, under a Rule 10b5-1 trading plan. Following this transaction, she directly holds 92,562 shares, including those from RSUs. The …

Ultragenyx (RARE) CFO sells stock under 10b5-1 plan, keeps 96,295 shares

Ultragenyx Pharmaceutical Inc.'s Chief Financial Officer, Howard Horn, sold 4,696 shares of common stock on August 3, 2026, for $24.92 per share under a Rule 10b5-1 trading plan. Following this transaction, Mr. Horn directly holds 96,295 shares, which include shares underlying Restricted Stock Units …

Exagen Q2 Earnings Call Highlights

Exagen Inc (XGN) reported record quarterly revenue of $19.9 million in Q2 2026, marking a 16% year-over-year increase, driven by record AVISE test volume and Pharma Services revenue. The company also significantly narrowed its adjusted EBITDA loss to $0.1 million and raised its full-year …

Earnings call transcript: Exagen tops Q2 2026 estimates, shares jump 20%

Exagen (XGN) reported strong Q2 2026 results, surpassing Wall Street expectations with record revenue of $19.9 million and narrowing its adjusted EBITDA loss to $0.1 million. The autoimmune-testing company also raised its full-year 2026 revenue guidance to $72 million-$75 million, driven by increased test …

Vistagen Therapeutics, Inc. Stockholders with Large Losses in VTG

Robbins LLP is reminding investors that a class action lawsuit has been filed against Vistagen Therapeutics, Inc. (NASDAQ: VTGN) on behalf of stockholders who purchased shares between April 1, 2024, and December 16, 2025. The lawsuit alleges that Vistagen misled investors regarding the viability …

Is Exagen Inc (XGN) Worth the Price After Q2 Earnings? Revenue Hits $19.9M but GF Score Indicates 56.3% Overvalued

Exagen Inc (XGN) reported Q2 2026 revenue of $19.9 million, surpassing analyst estimates and marking a 16% increase year-over-year, with a reduced net loss of $3.2 million. Despite strong growth and improved operational efficiency, GuruFocus rates the stock as 56.3% overvalued at its current …

IKNA Stock News Today | Earnings, Events & Price Alerts

Ikena Oncology (IKNA) is undergoing significant corporate changes, including a merger with Inmagene Biopharmaceuticals and a subsequent rebranding to ImageneBio, which will trade under the ticker IMA. The merger involves a private placement of $75 million and a 1-for-12 reverse stock split. Kristin Yarema …

Exagen (NASDAQ:XGN) Announces Quarterly Earnings Results

Exagen Inc. (NASDAQ: XGN) lifts Q2 2026 revenue to $19.9M

Exagen Inc. reported a significant increase in Q2 2026 revenue to $19.9 million, up from $17.2 million a year earlier, primarily driven by its AVISE® CTD autoimmune diagnostic test. The company narrowed its net loss to $3.2 million and improved its operating loss to …

EXAGEN INC. Q2 2026: Revenue $19.94M, EPS $(0.13) — 10-Q Summary

EXAGEN INC. (XGN) reported its Q2 2026 financial results, showing revenue of $19.94 million and a diluted EPS of $(0.13). The company achieved a narrower net loss of $3.2 million compared to $4.44 million in the prior year, driven by improved margins, higher test …

Exagen Q2 2026 slides: record revenue, stock surges 36%

Exagen Inc. reported record revenue of $19.9 million for Q2 2026, marking 16% year-over-year growth and exceeding analyst expectations. The company's stock surged 35.9% following the announcement, driven by strong quarterly performance and raised full-year guidance. Exagen is nearing profitability, with adjusted EBITDA loss …

Exagen (NASDAQ:XGN) Beats Q2 Estimates and Raises Full-Year Guidance

Agenus Inc expected to post earnings of 5 cents a share - Earnings Preview

Agenus Inc is projected to report earnings of 5 cents per share. This information is presented as an earnings preview by Refinitiv, shared through TradingView News. The full article is available to subscribers of TradingView.

Exagen Reports Record Second-Quarter Revenue and Narrows Losses, Raises Full-Year 2026 Guidance

Exagen (XGN) announced record second-quarter 2026 revenue of $19.9 million, a 16% increase year-over-year. Despite a net loss of $3.2 million, the company raised its full-year 2026 revenue guidance to $72 million to $75 million. Insider trading data shows recent sales by executives, while …

Guggenheim cuts Ultragenyx stock price target on trial uncertainty

Guggenheim has reduced its price target for Ultragenyx Pharma (NASDAQ:RARE) shares from $43 to $35, while maintaining a Buy rating, due to uncertainty surrounding the company's ASPIRE study readout in Q3 2026. The firm notes that an overwhelmingly positive result could significantly boost the …

Exagen Inc. Reports Second Quarter 2026 Financial Results

Exagen Inc. (Nasdaq: XGN) reported record total revenue of $19.9 million for the second quarter of 2026, a 16% increase year-over-year, and narrowed its adjusted EBITDA loss to $0.1 million. The company achieved a trailing twelve-month average selling price (ASP) of $446 for its …

Vistagen Therapeutics Inc expected to post a loss of 36 cents a share - Earnings Preview

Vistagen Therapeutics Inc is projected to report a loss of 36 cents per share, according to an earnings preview. The article indicates that this information is sourced from Refinitiv. Readers are prompted to access the full article through a paid subscription on TradingView.

IREDA Shares Fall 2% Despite Strong Q1 Profit Growth

Segall Bryant & Hamill LLC Lowers Holdings in Qiagen N.V. $QGEN

Segall Bryant & Hamill LLC reduced its stake in Qiagen N.V. by 24.5% in the first quarter, selling 36,110 shares but still retaining 111,177 shares worth approximately $4.45 million. Despite this reduction, other institutional investors like Groupe la Francaise, Janus Henderson Group PLC, Amundi, …

Exagen Inc. (XGN) Reports Q2 Loss, Beats Revenue Estimates

Exagen Inc. (XGN) reported a Q2 loss of $0.13 per share, exceeding the Zacks Consensus Estimate of a $0.19 loss and outperforming the prior year's loss of $0.18 per share. The company's revenues reached $19.94 million, surpassing the consensus estimate by 10.58% and the …

SRX Global acquires stake in Vistagen Therapeutics

SRX Global has acquired a minority equity stake in Vistagen Therapeutics, a Nasdaq-listed biotech company. The investment targets Vistagen's late-stage neuroscience pipeline, specifically its intranasal "pherine" product candidates. SRX Global believes Vistagen shares are undervalued and plans to engage with management and the board …